Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SER-214

Small molecule · Agonist of dopamine receptor · developed by Serina Therapeutics

Phase 1 Most advanced trial (none active)
SER Developer
1 Registered trials

What is SER-214?

SER-214 is a poly(2-ethyl-oxazoline) polymer conjugate of the dopamine agonist rotigotine, designed to provide continuous drug delivery after a single weekly injection. It is studied in Parkinson's disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
POZ-rotigotine
Drug type
Small molecule
Targets
dopamine receptor
Mechanism
Agonist of dopamine receptor
Therapy area
Neurology
Developer
Serina Therapeutics (SER)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02579473 Phase 1 Parkinson's Disease Unknown SER

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Parkinson's Disease

More from Serina Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SER page.

Follow SER, the company behind SER-214

See SER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SER catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.